TY - JOUR T1 - Evidence for immunity to SARS-CoV-2 from epidemiological data series JF - medRxiv DO - 10.1101/2020.07.22.20160028 SP - 2020.07.22.20160028 AU - Pablo Yubero AU - Alvar A. Lavin AU - Juan F. Poyatos Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/08/01/2020.07.22.20160028.abstract N2 - The duration of immunity to SARS-CoV-2 is uncertain. Delineating immune memory typically requires longitudinal serological studies that track antibody prevalence in the same cohort for an extended time. However, this information is needed in faster timescales. Notably, the dynamics of an epidemic where recovered patients become immune for any period should differ significantly from those of one where the recovered promptly become susceptible. Here, we exploit this difference to provide a reliable protocol that can estimate immunity early in an epidemic. We verify this protocol with synthetic data, discuss its limitations, and then apply it to evaluate human immunity to SARS-CoV-2 in mortality data series from New York City. Our results indicate that New York’s mortality figures are incompatible with immunity lasting anything below 105 or above 211 days (90% CI.), and set an example on how to assess immune memory in emerging pandemics before serological studies can be deployed.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by PhD fellowship BES-2016-079127 (P.Y.) and grant FIS2016-78781-R (J.F.P.) from the Spanish Ministerio de Economia y Competitividad and the European Social Fund.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:No oversight approval was required.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData availability is discussed in Data acquisition section https://github.com/CSSEGISandData/COVID-19 ER -